Poland· PL-100520929
Sephience
A various alimentary tract and metabolism products product containing sepiapterinum, registered in Poland by PTC Therapeutics International Ltd.. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sepiapterinum is registered in 4 of 19 countries.
Countries holding a registration under ATC A16AX (various alimentary tract and metabolism products), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Sepiapterinum · ATC A16AX
4 / 19 countries
- Finlandprice
- Ireland
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Sepiapterinum
- Manufacturer
- PTC Therapeutics International Ltd.
- Country
- Poland (PL)
- ATC code
- A16AX
- ATC class
- Various alimentary tract and metabolism products
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin03400930318881
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sepiapterinum in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesSephiencePTC Therapeutics Inc.
- SwitzerlandSephience 250 mg, Pulver zum EinnehmenPTC Therapeutics Switzerland GmbH
- CzechiaSEPHIENCEPTC Therapeutics International Limited, Dublin 2
- SpainSEPHIENCE 250 MG POLVO ORAL EN SOBREPtc Therapeutics International Limited
- FinlandSephiencePTC Therapeutics International Limited
- BelgiumSephience 250 mgPTC Therapeutics International
- IrelandSephience 250 mg oral powder in sachetPTC Therapeutics International Limited
- IcelandSephiencePTC Therapeutics International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sephience
- Liechtenstein · Sephience
- Norway · Sephience
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/98e1371a-26b8-4804-b885-a32c8ccead75 GET /v1/drugs/98e1371a-26b8-4804-b885-a32c8ccead75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek doustny w saszetce",
"source": "urpl",
"strength": "250 mg",
"packaging": "03400930318881 ¦ Rpz ¦ EU/1/25/1939/001 ¦ 162763\n30 saszetek",
"substance": "Sepiapterinum 250 mg",
"common_name": "Sepiapterinum",
"pl_product_id": "100520929",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sepiapterinum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.